SynthesisBMC gastroenterology2025
mRNA expression of NLRP3 and IL1B in inflammatory bowel diseases: a systematic review and meta-analysis.
Synthesis in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The NLRP3 inflammasome in physiological and dysfunctional host response in human sepsis and critical illness: a narrative review.Critical care (London, England) · 2026Review
- Article
- Macrophage pyroptosis in inflammatory bowel disease: mechanistic insights, pathological roles and treatment strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInflammatory bowel diseases (IBD) are chronic inflammatory conditions of the gastrointestinal tract. Clinical studies of IBD robustly show elevated interleukin 1β (IL-1β) levels in intestinal tissue, implicating the NLR family pyrin domain containing 3 (NLRP3) inflammasome, which controls IL-1β secretion in myeloid cells. In this study, we aimed to ground potential NLRP3 involvement in IBD in molecular evidence from human studies.
methodsThis systematic review and meta-analysis investigated NLRP3 and IL1B mRNA expression in biopsies of intestinal tissue and cells isolated from unstimulated blood of IBD patients compared to healthy controls (HCs), using standardized mean differences (SMD) [95% confidence interval (CI)], p-values and heterogeneity (I
resultsA systematic search in Medline and Embase identified 2218 records, with 30 studies describing 33 separate datasets meeting inclusion criteria. Meta-analysis revealed consistently higher NLRP3 and IL1B mRNA expression in intestinal tissue of IBD patients (24 datasets, n = 3912; NLRP3: SMD = 0.53 [0.36, 0.70], p < 0.001, I²=66%; IL1B: SMD = 0.95 [0.66, 1.24], p < 0.001, I²=89%). In blood, IL1B expression was significantly elevated (9 datasets, n = 1921; SMD = 0.20 [0.06, 0.33], p = 0.003, I²=15%), while NLRP3 expression showed no significant increase (SMD = 0.12 [-0.16, 0.40], p = 0.40, I²=78%). SMDs of NLRP3 and IL1B in tissue strongly and positively correlated with each other (rho = 0.854 [0.687, 0.935], p < 0.001).
conclusionWe found upregulation of both NLRP3 and IL1B mRNA in intestinal tissue of IBD patients, which highly correlated across 24 studies, reinforcing the role of the NLRP3 inflammasome in IBD and its potential as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.